Sintx Technologies, Inc.
No SEC Form 4 filings for $SINT in the last 30 days.
See all $SINT insider activity →Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone
Ascendiant Capital maintained a Buy rating on SINTX Technologies with a $12.50 price target, implying 460.5% upside from the Sep 30 close of $2.23. The firm cited strong growth potential in the orthopedic device market and attractive valuation.
Sintx Technologies reported a Q2 2026 transition toward a commercial biomaterials and medical technology platform. Revenue rose 199% on OEM industrial demand and pricing, with gross margin near 62%. Management cited a $3.2M backlog to convert into revenue, SiNAPTIC wedge first clinical use in March 2026, and Q3/Q4 revenue guidance of $0.9M-$1.1M and $1.0M-$1.3M, while noting going-concern financing needs.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning SINT (Sintx Technologies, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent SINT coverage spans financial news, earnings and corporate actions.
The surprise revenue beat suggests narrowed losses and may prompt short-term buying pressure.
Ascendiant Capital maintained a Buy rating on SINTX Technologies with a $12.50 price target, implying 460.5% upside from the Sep 30 close of $2.23. The firm cited strong growth potential in the orthopedic device market and attractive valuation.
Guidance and backlog timing plus going-concern financing plans are likely to drive near-term risk premium and trading volatility.
This is a company-specific disclosure tied to its quarterly reporting and revenue outlook, but the scraped text does not include the actual financial figures or guidance numbers.
The 8-K discloses a warrant issuance (MedTech Ceramics, LP as holder) that can create future dilution/overhang depending on exercise terms and likelihood.
AlphAI scores every news story that mentions SINT with an AI model for sentiment and relevance, and aggregates insider trades from Sintx Technologies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Sintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone
2 min readAscendiant Capital maintained a Buy rating on SINTX Technologies with a $12.50 price target, implying 460.5% upside from the Sep 30 close of $2.23. The firm cited strong growth potential in the orthopedic device market and attractive valuation.
1 min readSintx Technologies reported a Q2 2026 transition toward a commercial biomaterials and medical technology platform. Revenue rose 199% on OEM industrial demand and pricing, with gross margin near 62%. Management cited a $3.2M backlog to convert into revenue, SiNAPTIC wedge first clinical use in March 2026, and Q3/Q4 revenue guidance of $0.9M-$1.1M and $1.0M-$1.3M, while noting going-concern financing needs.
6 min readSintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives SALT LAKE CITY, Utah – August 11, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a
2 min readSintx Technologies, Inc. (SINT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.2 3 ex4-2.htm EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER T
3 min readSyntiant Corp. said it appointed Adam Spice, CFO of Rocket Lab (Nasdaq: RKLB), and David Lam, CIO of Lam Frontier Technologies, to its board. The company cited Spice’s 25+ years of aerospace/technology finance leadership and Lam’s 25+ years investing in semiconductors and AI. Syntiant said the appointments support its growth and investor engagement.
2 min readMaxim Group reiterated a “Buy” rating on Sintx Technologies (NASDAQ:SINT) and set a $6.00 price target, implying 169.66% upside from the prior close, according to Benzinga. Other firms cited include Ascendiant (cut target to $12, Buy), Weiss (sell), and HC Wainwright (Buy, $10). SINT last traded at $2.23. The company reported Q EPS of ($0.70) vs ($0.66) consensus and revenue of $0.38M vs $0.30M.
4 min readClinical evaluation of the product by design surgeons completed, driving early commercial momentum ...
4 min readDoes SINTX TECHNOLOGIES, INC. (SINT) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 min readNew U.S. Patent reinforces competitive advantage and enables broader licensing and product opportunities across key markets
2 min read
